Redox state of dipyridamole is a critical determinant for its beneficial antioxidant and antiinflammatory effects

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 4, 2007, Pages 449-457

  Chakrabarti, Subrata ^a   Blair, Price ^a   Wu, Cindy ^a   Freedman, Jane E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Dipyridamole; HUVECs; NF B; Platelets; Redox

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; CD40 LIGAND; COLLAGEN; CUPRIC ION; DIPYRIDAMOLE; FERROZINE; HORSERADISH PEROXIDASE; HYDROGEN PEROXIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; FLUORESCENCE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION; THROMBOCYTE RELEASE REACTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BIPHENYL COMPOUNDS; BLOOD PLATELETS; CD40 LIGAND; CELL ADHESION MOLECULES; DIPYRIDAMOLE; ENDOTHELIAL CELLS; FERRIC COMPOUNDS; HL-60 CELLS; HUMANS; HYDRAZINES; HYDROGEN PEROXIDE; I-KAPPA B PROTEINS; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; NF-KAPPA B; OXIDATION-REDUCTION; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ADHESIVENESS; REACTIVE OXYGEN SPECIES; SPECTROMETRY, FLUORESCENCE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37349065481     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31813542db     Document Type: Article

References (32)

1. Gresele P, Zoja C, Deckmyn H, et al. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost. 1983;50:852-856.
2. Gresele P, Arnout J, Deckmyn H, et al. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb Haemost. 1986;55:12-18.
3. Aszodi A, Pfeifer A, Ahmad M, et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. Embo J. 1999;18:37-48.
4. Geiger J. Inhibitors of platelet signal transduction as anti-aggregatory drugs. Expert Opin Investig Drugs. 2001;10:865-890.
5. Aktas B, Utz A, Hoenig-Liedl P, et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies. Stroke. 2003;34:764-769.
6. Nepomuceno MF, Alonso A, Pereira-da-Silva L, et al. Inhibitory effect of dipyridamole and its derivatives on lipid peroxidation in mitochondria. Free Radic Biol Med. 1997;23:1046-1054.
7. Iuliano L, Piccheri C, Coppola I, et al. Fluorescence quenching of dipyridamole associated to peroxyl radical scavenging: a versatile probe to measure the chain breaking antioxidant activity of biomolecules. Biochim Biophys Acta. 2000;1474:177-182.
8. Kusmic C, Petersen C, Picano E, et al. Antioxidant effect of oral dipyridamole during cerebral hypoperfusion with human carotid endarterectomy. J Cardiovasc Pharmacol. 2000;36:141-145.
9. Kusmic C, Picano E, Busceti CL, et al. The antioxidant drug dipyridamole spares the vitamin E and thiols in red blood cells after oxidative stress. Cardiovasc Res. 2000;47:510-514.
10. Ruggiero AC, Nepomuceno MF, Jacob RF, et al. Antioxidant effect of dipyridamole (DIP) and its derivative RA 25 upon lipid peroxidation and hemolysis in red blood cells. Physiol Chem Phys Med NMR. 2000;32:35-48.
11. Chakrabarti S, Vitseva O, Iyu D, et al. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J Pharmacol Exp Ther. 2005;315:494-500.
12. Almeida LE, Imasato H, Tabak M. Enzymatic oxidation of dipyridamole in homogeneous and micellar solutions in the horseradish peroxidase-hydrogen peroxide system. Biochim Biophys Acta. 2006;1760:216-226.
13. Chen TH, Kao YC, Chen BC, et al. Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells. Eur J Pharmacol. 2006;541:138-146.
14. Iuliano L, Colavita AR, Camastra C, et al. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol. 1996;119:1438-1446.
15. Yoshida H, Sasaki K, Namiki Y, et al. Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase. Atherosclerosis. 2005;179:97-102.
16. Dang PM, Stensballe A, Boussetta T, et al. A specific p47-serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J Clin Invest. 2006;116:2033-2043.
17. Chakrabarti S, Varghese S, Vitseva O, et al. CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol. 2005;25:2428-2434.
18. Oshrine B, Malinin A, Pokov A, et al. Criticality of pH for accurate fluorometric measurements of dipyridamole levels in biological fluids. Methods Find Exp Clin Pharmacol. 2005;27:95-100.
19. Selley ML, Czeti AL, McGuiness JA, et al. Dipyridamole inhibits the oxidative modification of low density lipoprotein. Atherosclerosis. 1994;111:91-97.
20. Carcamo JM, Pedraza A, Borquez-Ojeda O, et al. Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry. 2002;41:12995-13002.
21. Hellerbrand C, Jobin C, Iimuro Y, et al. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology. 1998;27:1285-1295.
22. Iuliano L, Ghiselli A, Alessandri C, et al. Superoxide anion scavenging property of dipyridamole. Thromb Haemost. 1989;61:149.
23. Vargas F, Cheng AT, Velutini G, et al. In vitro antioxidant and photo-oxidant properties of dipyridamole. Int J Toxicol. 2001;20:363-368.
24. Vargas F, Rivas C, Diaz Y, et al. Antioxidant properties of dipyridamole as assessed by chemiluminescence. Pharmazie. 2003;58:817-823.
25. Blake AD. Dipyridamole is neuroprotective for cultured rat embryonic cortical neurons. Biochem Biophys Res Commun. 2004;314:501-504.
26. Iuliano L, Violi F, Pedersen JZ, et al. Free radical-mediated platelet activation by hemoglobin released from red blood cells. Arch Biochem Biophys. 1992;299:220-224.
27. Pedulli GF, Lucarini M, Marchesi E, et al. Medium effects on the antioxidant activity of dipyridamole. Free Radic Biol Med. 1999;26:295-302.
28. Horstrup K, Jablonka B, Honig-Liedl P, et al. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem. 1994;225:21-27.
29. Chakrabarti S, Blair P, Freedman JE. CD40-40L signaling in vascular inflammation. J Biol Chem. 2007;282:18307-18317.
30. Palmer HJ, Paulson KE. Reactive oxygen species and antioxidants in signal transduction and gene expression. Nutr Rev. 1997;55:353-361.
31. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999;85:753-766.
32. Morel Y, Barouki R. Repression of gene expression by oxidative stress. Biochem J. 1999;342 Pt 3:481-496.